Q3 EPS Estimate for Capricor Therapeutics Cut by Analyst

Key Points

• HC Wainwright cut Capricor Therapeutics’ Q3 2026 EPS estimate to a loss of $0.73 per share from $0.63, while maintaining a Neutral rating. The firm also lowered its estimates for Q4 2026, fiscal 2026 and fiscal 2027.
• Capricor reported a quarterly loss of $0.70 per share, missing the consensus estimate of a $0.59 loss. The stock opened at $7.45, far below its 52-week high of $40.37.
• Analyst sentiment remains cautious, with the stock carrying a consensus Hold rating and a $29.15 price target; the company also faces a securities-fraud class action alleging misstatements involving Deramiocel and clinical-trial data.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Capricor Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($0.73) for the quarter, down from their prior estimate of ($0.63). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Capricor Therapeutics' Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.75) EPS and FY2027 earnings at ($2.84) EPS.

A number of other research analysts have also weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Roth Capital downgraded Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price target for the company. in a report on Monday, July 27th. Oppenheimer reissued a "market perform" rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Wall Street Zen cut Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Finally, B. Riley Financial downgraded shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $10.00 price objective on the stock. in a report on Monday, July 27th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $29.15.

Capricor Therapeutics Stock Performance

CAPR stock opened at $7.45 on Tuesday. The business has a 50-day simple moving average of $17.81 and a two-hundred day simple moving average of $25.28. The company has a market capitalization of $431.43 million, a P/E ratio of -3.04 and a beta of 0.54. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11).

Insider Buying and Selling at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 25,000 shares of company stock valued at $759,158. 9.20% of the stock is owned by insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at $49,062,000. RA Capital Management L.P. bought a new position in Capricor Therapeutics in the 4th quarter valued at $43,516,000. Darwin Global Management Ltd. purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $23,168,000. Finally, SB Capital Management Inc purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $11,544,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: A securities-fraud class action has been filed against Capricor and certain executives. The lawsuit alleges that the company made material misstatements or omissions about Deramiocel, the HOPE-3 clinical trial’s statistical analysis plan, FDA compliance, and the integrity of data supporting its Biologics License Application. The allegations relate to a previously reported 64% stock decline; they have not been proven in court. Capricor securities-fraud lawsuit
• Negative Sentiment: Multiple law firms are publicizing the class action and urging investors who purchased CAPR shares between December 17, 2025, and July 26, 2026, to seek lead-plaintiff status by late September. The repeated litigation notices may keep legal and clinical-data concerns in focus, potentially limiting buying interest. Capricor class-action deadline
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across several periods while maintaining a Neutral rating. Estimates were reduced to losses of $0.73 per share for both the third and fourth quarters of 2026, $2.75 for fiscal 2026, and $2.84 for fiscal 2027, from prior forecasts of $0.63, $0.60, $2.43, and $2.57, respectively. The revisions reinforce expectations for sustained cash burn and larger losses. HC Wainwright Capricor estimates
• Neutral Sentiment: Investor concerns were also amplified by reports that Capricor’s recent second-quarter earnings call did not include a management question-and-answer session with analysts, reducing near-term clarity on the company’s clinical, regulatory, and financing outlook. Capricor Q2 earnings and lawsuit update

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source